ArticleTranslational lung cancer research2025
Prognostic biomarkers for extensive-stage small cell lung cancer receiving amrubicin following failure of chemoimmunotherapy: a retrospective cohort study.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Little is known about whether prior chemoimmunotherapy (CTI) affects the efficacy of sequential treatment in patients with extensive-stage (ES) small-cell lung cancer (SCLC). Our preliminary study explored what kinds of biomarkers are associated with the outcomes of CTI followed by amrubicin (AMR) as a second-line treatment. Methods: We retrospectively evaluated 45 patients with relapsed SCLC who underwent CTI followed by AMR monotherapy from December 2019 to December 2023. Clinical data and inflammatory and nutritional factors, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, systemic immune-inflammation index, prognostic nutritional index (PNI), advanced lung cancer inflammation index (ALI), and Glasgow prognostic score before initial treatment of AMR, were analyzed to determine prognostic predictors. Survival analyses of variables were performed using the COX proportional hazards model. Results: The objective responses for prior CTI and AMR were 40.5% and 60.0%, respectively. Progression-free survival (PFS) and overall survival (OS) after AMR were closely related to the NLR and ALI (or PNI). However, there were no significant factors associated with AMR response. Univariate analysis identified NLR and ALI as significant predictors of PFS, and the presence of prior immune checkpoint inhibitor (ICI) maintenance, NLR, ALI, and duration from ICI to progressive disease as significant predictors of OS. Multivariate analysis demonstrated that the NLR was an independent prognostic factor for predicting worse PFS and OS after AMR administration. Conclusions: NLR was identified as a significant biomarker for predicting AMR outcomes after prior CTI in patients with ES-SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.